RxDoctor Payments Data

Cecilia Garcia, APRN

Family · Baltimore, MDNPI 1932770245

Payments from drug & device makers

$959in general payments, 2019–2025

Across 10 payments — averaging $95.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Recor Medical Inc$159
  • Heartflow, Inc.$153
  • Edwards Lifesciences$150
  • Novartis$126
  • Amgen$120
  • E.r. Squibb & Sons, L.L.C.$109
  • plus $142 from 3 others

What the payments were for

  • Food & beverage$959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$56,828
Medicare patients
407
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$137,146
EntrestoSacubitril/Valsartan33$51,517
XareltoRivaroxaban23$27,774
JardianceEmpagliflozin14$21,864
Rosuvastatin Calcium76$2,587
Atorvastatin Calcium126$1,555
Metoprolol Succinate103$1,461
Valsartan27$1,175
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$1,111
Ezetimibe24$973
ClopidogrelClopidogrel Bisulfate42$634
Isosorbide Mononitrate ErIsosorbide Mononitrate30$539
Losartan Potassium77$485
Bumetanide13$383
Hydralazine Hcl21$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$126$51,51733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →